Gossamer Bio, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Revenue from contracts with collaborators | $9,889 | $— |
| Total revenue | 9,889 | — |
| Operating expenses: | ||
| Research and development | 38,041 | 32,392 |
| General and administrative | 8,658 | 9,567 |
| Total operating expenses | 46,699 | 41,959 |
| Loss from operations | (36,810) | (41,959) |
| Other income (expense) | ||
| Interest income | 294 | 344 |
| Interest expense | (2,746) | (3,129) |
| Other income, net | 2,624 | 2,816 |
| Total other income, net | 172 | 31 |
| Net loss | $(36,638) | $(41,928) |
| Other comprehensive loss: | ||
| Foreign currency translation | (1,903) | (119) |
| Unrealized loss on marketable securities | (110) | (159) |
| Other comprehensive loss | (2,013) | (278) |
| Comprehensive loss | $(38,651) | $(42,206) |
| Net loss per share, basic and diluted | $(0.16) | $(0.19) |
| Weighted average common shares outstanding, basic and diluted | 226,818,051 | 225,735,236 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.